JP2006515744A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515744A5 JP2006515744A5 JP2004541534A JP2004541534A JP2006515744A5 JP 2006515744 A5 JP2006515744 A5 JP 2006515744A5 JP 2004541534 A JP2004541534 A JP 2004541534A JP 2004541534 A JP2004541534 A JP 2004541534A JP 2006515744 A5 JP2006515744 A5 JP 2006515744A5
- Authority
- JP
- Japan
- Prior art keywords
- mhc class
- epitope
- presenting
- key
- terminal element
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000043129 MHC class I family Human genes 0.000 claims 11
- 108091054437 MHC class I family Proteins 0.000 claims 11
- 102000043131 MHC class II family Human genes 0.000 claims 7
- 108091054438 MHC class II family Proteins 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 108010028930 invariant chain Proteins 0.000 claims 6
- 230000000890 antigenic effect Effects 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 210000004896 polypeptide structure Anatomy 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/245,871 US20030235594A1 (en) | 1999-09-14 | 2002-09-17 | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US10/253,286 US7179645B2 (en) | 2002-09-24 | 2002-09-24 | Ii-Key/antigenic epitope hybrid peptide vaccines |
| PCT/US2003/028574 WO2004030616A2 (en) | 2002-09-17 | 2003-09-12 | Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006515744A JP2006515744A (ja) | 2006-06-08 |
| JP2006515744A5 true JP2006515744A5 (cg-RX-API-DMAC7.html) | 2007-10-18 |
Family
ID=32072825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004541534A Pending JP2006515744A (ja) | 2002-09-17 | 2003-09-12 | Ｉｉ−Ｋｅｙ／抗原性エピトープハイブリッドペプチドワクチン |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1556072B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006515744A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003294220A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2499123A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004030616A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601351B1 (en) | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| EP2332971B1 (en) * | 2004-06-17 | 2016-02-17 | MannKind Corporation | Epitope analogs |
| WO2006138675A2 (en) | 2005-06-15 | 2006-12-28 | The Ohio State University Research Foundation | Her-2 peptides |
| US20080095798A1 (en) * | 2006-10-18 | 2008-04-24 | Robert Humphreys | Ii-key enhanced vaccine potency |
| GB0706070D0 (en) * | 2007-03-28 | 2007-05-09 | Scancell Ltd | Nucleic acids |
| US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
| JP2012050440A (ja) * | 2011-09-16 | 2012-03-15 | Chiba Univ | ヒトＴｈ１／Ｔｈ２分化誘導の評価方法 |
| EP3964232A1 (en) * | 2012-10-30 | 2022-03-09 | Aravax Pty Ltd | Novel immunotherapeutic molecules and uses thereof |
| EP3049098A4 (en) | 2013-09-25 | 2017-08-16 | Aravax Pty Ltd | Novel immunotherapeutic composition and uses thereof |
| ES2952959T3 (es) * | 2015-03-27 | 2023-11-07 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra diversos tumores (SEQ ID N.º 25 - MXRA5-003) |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| US11485768B2 (en) * | 2016-04-19 | 2022-11-01 | Imcyse Sa | Immunogenic CD1d binding peptides |
| CN108129558B (zh) * | 2017-12-21 | 2021-10-12 | 中国医学科学院北京协和医院 | 一种桦树花粉主要致敏蛋白Bet v 8的提取和分离纯化方法及应用 |
| US20230000908A1 (en) * | 2019-09-11 | 2023-01-05 | Ohio State Innovation Foundation | Engineered cells and uses thereof |
| WO2023240295A2 (en) * | 2022-06-10 | 2023-12-14 | Ayass Bioscience Llc | Food allergen processing and desensitization by aptamers |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| EP0190205B1 (en) | 1984-07-24 | 1992-10-21 | Coselco Mimotopes Pty. Ltd. | Method for determining mimotopes |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US6133029A (en) | 1988-03-21 | 2000-10-17 | Chiron Corporation | Replication defective viral vectors for infecting human cells |
| US5194425A (en) | 1988-06-23 | 1993-03-16 | Anergen, Inc. | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
| US5539084A (en) | 1989-02-17 | 1996-07-23 | Coselco Mimotopes Pty. Ltd. | Method for the use and synthesis of peptides |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| EP0497922B1 (en) | 1989-10-24 | 2002-01-30 | Chiron Corporation | Infective protein delivery system |
| US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
| AU668347B2 (en) | 1990-11-21 | 1996-05-02 | Torrey Pines Institute For Molecular Studies | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| ATE152915T1 (de) | 1991-11-29 | 1997-05-15 | Viagene Inc | Immuntherapeutische vektorkonstrukte gegen krebs |
| US5679527A (en) | 1992-03-25 | 1997-10-21 | Antigen Express, Inc. | Modification of polypeptide structure |
| AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5559028A (en) | 1993-05-19 | 1996-09-24 | Antigen Express, Inc. | Methods of enhancing or antigen presentation to T cells inhibiting |
| WO1995004817A1 (en) | 1993-08-06 | 1995-02-16 | Cytel Corporation | Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl |
| US5874214A (en) | 1995-04-25 | 1999-02-23 | Irori | Remotely programmable matrices with memories |
| US5910300A (en) | 1995-11-01 | 1999-06-08 | Bracco Research S.A. | Amphiphilic linkers for coupling administrable diagnostically or physiologically active agents and bioselective targeting compounds |
| AU3307497A (en) | 1996-06-26 | 1998-01-14 | Antigen Express, Inc. | Immunotherapy by modulation of antigen presentation |
| US6432409B1 (en) | 1999-09-14 | 2002-08-13 | Antigen Express, Inc. | Hybrid peptides modulate the immune response |
-
2003
- 2003-09-12 WO PCT/US2003/028574 patent/WO2004030616A2/en not_active Ceased
- 2003-09-12 CA CA002499123A patent/CA2499123A1/en not_active Abandoned
- 2003-09-12 EP EP03789700A patent/EP1556072B1/en not_active Expired - Lifetime
- 2003-09-12 JP JP2004541534A patent/JP2006515744A/ja active Pending
- 2003-09-12 AU AU2003294220A patent/AU2003294220A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2337969C (en) | Compound and method for the prevention and/or the treatment of allergy | |
| US10772934B2 (en) | Highly active polypeptides and methods of making and using the same | |
| US5580563A (en) | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof | |
| JP2006515744A5 (cg-RX-API-DMAC7.html) | ||
| Kaumaya et al. | Peptide vaccines incorporating a ‘promiscuous’ T‐cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity | |
| JP5751741B2 (ja) | 免疫原性組成物および使用法 | |
| JP3802049B2 (ja) | Ｈｉｖに対する中和性抗体および細胞障害性ｔリンパ球を誘発する複合合成ペプチド構築物 | |
| JPH04502760A (ja) | エイズの診断，予防および治療に有効な新規ｈｉｖ蛋白質およびペプチド | |
| JP2020506690A5 (cg-RX-API-DMAC7.html) | ||
| JP2006020648A5 (cg-RX-API-DMAC7.html) | ||
| JP2003529319A (ja) | ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法 | |
| JP2001502658A (ja) | 非樹状中心骨格ペプチド担体 | |
| JPH09505559A (ja) | 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変 | |
| Huang et al. | Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine | |
| CN1054772A (zh) | 合成多肽 | |
| RU2337922C9 (ru) | ИЗОЛИРОВАННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ НЕЙТРАЛИЗУЮЩЕГО ЭПИТОПА БЕЛКА p17 ВИРУСА ВИЧ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ВАКЦИН, А ТАКЖЕ НЕЙТРАЛИЗУЮЩИЕ АНТИ-p17-АНТИТЕЛА, СПЕЦИФИЧЕСКИ РАСПОЗНАЮЩИЕ УКАЗАННЫЙ НЕЙТРАЛИЗУЮЩИЙ ЭПИТОП | |
| Curicio‐Vonlanthen et al. | Molecular parameters in melittin immunogenicity | |
| JP2002536384A (ja) | Ｔヘルパー細胞エピトープ | |
| JPH07506374A (ja) | う蝕予防用合成ペプチドワクチン | |
| US20030152581A1 (en) | Compound and method for the prevention and/or the treatment of allergy | |
| Ferru et al. | Analysis of the immune response elicited by a multiple antigen peptide (MAP) composed of two distinct protective antigens derived from the parasite Schistosoma mansoni | |
| Dakappagari et al. | Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T‐cell responses in HLA‐A* 201 mice | |
| ES2322253T3 (es) | Utilizacion de mezclas de lipopeptidos para la fabricacion de vacunas. | |
| JPH07505878A (ja) | Ｈｉｖエンベロープ糖タンパク質から誘導された合成ポリペプチド | |
| JPS58222031A (ja) | 合成ワクチン |